Please select the option that best describes you:
Topics:
Radiation Oncology • Neuro-Oncology
How do you manage limited intracranial disease from a metastatic large cell neuroendocrine tumor?
Do you offer WBRT or SRS? If you prefer SRS, do you follow up with WBRT?
Answer from: Radiation Oncologist at Academic Institution
In our practice we are moving to focal management of limited intracranial disease for all pathologies, pushing WBRT out to last resort status.LCNEC is a heterogeneous disease (Hiroshima K, Mino-Kenudson M. Transl Lung Cancer Res. 2017) with variable response to chemo therapy. Even more unclear is it...
Sign in or Register to read more